DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
作者信息
Bae Ji Cheol
机构信息
Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
出版信息
Endocrinol Metab (Seoul). 2022 Dec;37(6):858-860. doi: 10.3803/EnM.2022.605. Epub 2022 Dec 26.
Abstract
摘要
相似文献
1
DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
Endocrinol Metab (Seoul). 2022 Dec;37(6):858-860. doi: 10.3803/EnM.2022.605. Epub 2022 Dec 26.
2
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Ann Pharmacother. 2021 Jan;55(1):65-79. doi: 10.1177/1060028020935105. Epub 2020 Jun 22.
3
Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.
Curr Vasc Pharmacol. 2015;13(5):649-57. doi: 10.2174/1570161112666141121112612.
4
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Clin Drug Investig. 2016 Apr;36(4):313-9. doi: 10.1007/s40261-016-0383-1.
5
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
Diabetes Metab. 2020 Nov;46(6):427-441. doi: 10.1016/j.diabet.2019.12.007. Epub 2020 Jan 7.
6
Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis.
Curr Diabetes Rev. 2021;17(5):e101120187811. doi: 10.2174/1573399816999201110195634.
7
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28.
8
Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial.
Diabetes Obes Metab. 2022 Apr;24(4):752-756. doi: 10.1111/dom.14623. Epub 2021 Dec 27.
9
Combined treatment of dipeptidyl peptidase-4 inhibitor and exercise training improves lipid profile in KK/Ta mice.
Exp Physiol. 2019 Jul;104(7):1051-1060. doi: 10.1113/EP087449. Epub 2019 May 22.
10
Management of type 2 diabetes mellitus in chronic kidney disease.
Curr Med Res Opin. 2015 Jan;31(1):95-7. doi: 10.1185/03007995.2014.977993. Epub 2014 Oct 28.
引用本文的文献
1
Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome.
Int J Mol Sci. 2025 Apr 7;26(7):3448. doi: 10.3390/ijms26073448.
2
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment.
J Clin Med. 2025 Jan 10;14(2):428. doi: 10.3390/jcm14020428.
3
Impact of Dipeptidyl Peptidase-4 Inhibitors on Aminotransferases Levels in Patients with Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trial.
Curr Ther Res Clin Exp. 2024 Dec 4;102:100768. doi: 10.1016/j.curtheres.2024.100768. eCollection 2025.
4
Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective.
Diabetes Metab J. 2024 May;48(3):327-339. doi: 10.4093/dmj.2023.0350. Epub 2024 Feb 2.
本文引用的文献
1
Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction.
Endocrinol Metab (Seoul). 2022 Dec;37(6):918-928. doi: 10.3803/EnM.2022.1530. Epub 2022 Nov 15.
2
The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018.
Endocrinol Metab (Seoul). 2022 Jun;37(3):455-465. doi: 10.3803/EnM.2022.1434. Epub 2022 Jun 21.
3
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.
Obesity (Silver Spring). 2021 Nov;29(11):1950-1960. doi: 10.1002/oby.23263. Epub 2021 Sep 23.
4
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
Diabetes Care. 2021 Feb;44(2):399-406. doi: 10.2337/dc20-1997. Epub 2020 Dec 21.
5
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease.
Clin Mol Hepatol. 2020 Oct;26(4):430-443. doi: 10.3350/cmh.2020.0137. Epub 2020 Aug 14.
6
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
7
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.
8
Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.
Mol Metab. 2017 Oct;6(10):1254-1263. doi: 10.1016/j.molmet.2017.07.016. Epub 2017 Aug 4.
9
NAFLD: a multisystem disease.
J Hepatol. 2015 Apr;62(1 Suppl):S47-64. doi: 10.1016/j.jhep.2014.12.012.
10
Dipeptidyl peptidase-4: a key player in chronic liver disease.
World J Gastroenterol. 2013 Apr 21;19(15):2298-306. doi: 10.3748/wjg.v19.i15.2298.
Zotero 插件